| Identification | Back Directory | [Name]
2-PyrazinecarboxaMide, 3,5-diaMino-6-chloro-N-[[[4-[4-(2,3-dihydroxypropoxy)phenyl]butyl]aMino]iMinoMethyl]-, Methanesulfonate | [CAS]
587879-54-7 | [Synonyms]
P552
P-552
P 552
KM003
KM-003
KM 003
KM-003 (sulfite)
3,5-Diamino-6-chloro-N-(N-{4-[4-(2,3-dihydroxypropoxy)phenyl]butyl}carbamimidoyl)pyrazine-2-carboxam
3-(4-(4-(3-(3,5-Diamino-6-chloropyrazine-2-carbonyl)guanidino)butyl)phenoxy)-2-hydroxypropyl methanesulfonate
(E)-3,5-diamino-6-chloro-N-((2-(4-(4-(2,3-dihydroxypropoxy)phenyl)butyl)hydrazono)methyl)pyrazine-2-carboxamide
3,5-Diamino-6-chloro-N-(N-{4-[4-(2,3-dihydroxypropoxy)phenyl]butyl}carbamimidoyl)pyrazine-2-carboxamidemethanesulfonate(1:1)
2-PyrazinecarboxaMide, 3,5-diaMino-6-chloro-N-[[[4-[4-(2,3-dihydroxypropoxy)phenyl]butyl]aMino]iMinoMethyl]-, Methanesulfonate | [Molecular Formula]
C20H28ClN7O6S | [MDL Number]
MFCD27995553 | [MOL File]
587879-54-7.mol | [Molecular Weight]
529.998 |
| Hazard Information | Back Directory | [Uses]
P552-02 (552-02) mesylate is a sodium channel blocker that is potentially used for the treatment of cystic fibrosis, exhibiting biological activity that enhances mucociliary clearance in the lungs while minimizing the risk of hyperkalaemia. | [References]
[1] NVP-QBE170: an inhaled blocker of the epithelial sodium channel with a reduced potential to induce hyperkalaemia DOI:10.1111/bph.13075 |
|
| Company Name: |
T&W GROUP
|
| Tel: |
021-61551611 13296011611 |
| Website: |
www.trustwe.com/ |
|